Approval · Notice of Compliance 29227 · 2022
INTELENCE: Notice of Compliance 29227
Issued October 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29227
- Date
- October 14, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph (PM) with additional guidance on dispersion of etravirine tablets in liquid and PM conversion to the 2020 master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INTELENCE | Not yet assigned | — |
Medicinal ingredients
- ETRAVIRINE 25 MG per TAB
- ETRAVIRINE 100 MG per TAB
- ETRAVIRINE 200 MG per TAB